0001209191-21-008231.txt : 20210205 0001209191-21-008231.hdr.sgml : 20210205 20210205175043 ACCESSION NUMBER: 0001209191-21-008231 CONFORMED SUBMISSION TYPE: 5 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210205 DATE AS OF CHANGE: 20210205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Galante Joseph C CENTRAL INDEX KEY: 0001632384 FILING VALUES: FORM TYPE: 5 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33637 FILM NUMBER: 21597581 MAIL ADDRESS: STREET 1: 111 TENTH AVENUE STREET 2: SUITE 200 CITY: NASHVILLE STATE: TN ZIP: 37203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087294 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE, STATE: TN ZIP: 37203 BUSINESS PHONE: 615-255-0068 MAIL ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE STATE: TN ZIP: 37203 5 1 doc5.xml FORM 5 SUBMISSION X0306 5 2020-12-31 0 0 1 0001087294 CUMBERLAND PHARMACEUTICALS INC CPIX 0001632384 Galante Joseph C 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203 1 0 0 0 Common Stock 2020-10-09 4 L 0 75 3.25 A 27217 D Common Stock 2020-10-12 4 L 0 75 3.23 A 27292 D Common Stock 2020-10-13 4 L 0 75 3.21 A 27367 D Common Stock 2020-10-14 4 L 0 75 3.14 A 27442 D Common Stock 2020-10-15 4 L 0 75 3.07 A 27517 D Common Stock 2020-10-16 4 L 0 75 3.07 A 27592 D Common Stock 2020-10-19 4 L 0 75 3.03 A 27667 D Common Stock 2020-10-20 4 L 0 75 3.04 A 27742 D Common Stock 2020-10-21 4 L 0 75 3.04 A 27817 D Common Stock 2020-10-22 4 L 0 75 3.08 A 27892 D Common Stock 2020-10-23 4 L 0 75 3.04 A 27967 D Common Stock 2020-10-26 4 P 0 75 3.02 A 28042 D Common Stock 2020-10-27 4 P 0 75 3.06 A 28117 D Common Stock 2020-10-28 4 P 0 75 2.97 A 28192 D Common Stock 2020-10-29 4 P 0 75 3.02 A 28267 D Common Stock 2020-10-30 4 P 0 75 2.99 A 28342 D Common Stock 2020-11-02 4 P 0 75 2.97 A 28417 D Common Stock 2020-11-03 4 P 0 75 2.99 A 28492 D Common Stock 2020-11-04 4 P 0 75 3.01 A 28567 D Common Stock 2020-11-05 4 P 0 75 2.98 A 28642 D Common Stock 2020-11-06 4 P 0 75 2.99 A 28717 D Common Stock 2020-11-09 4 P 0 75 3.06 A 28792 D Common Stock 2020-11-10 4 P 0 75 3.09 A 28867 D Common Stock 2020-11-11 4 P 0 75 3.12 A 28942 D Common Stock 2020-11-12 4 P 0 75 3.03 A 29017 D Common Stock 2020-11-13 4 P 0 75 3.04 A 29092 D Common Stock 2020-11-16 4 P 0 75 3.05 A 29167 D Common Stock 2020-11-17 4 P 0 75 2.96 A 29242 D Common Stock 2020-11-18 4 P 0 75 3.01 A 29317 D Common Stock 2020-11-19 4 P 0 75 2.98 A 29392 D The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Filing 2 of 3 Joseph C. Galante by /s/ Michael Bonner as attorney-in-fact 2021-02-05